Molecular Partners, a Swiss developer of DARPins, a novel class of therapeutic proteins, has appointed Lisa Rojkjaer as chief medical officer.
Rojkjaer is a board-certified haematologist with more than 10 years’ experience in drug development and commercialisation in the biotech and pharma industries. She will be heading up all clinical activities at Molecular Partners by identifying and prioritising clinical development programmes to broaden the company’s pipeline.
Prior to joining Molecular Partners, Rojkjaer led all proprietary clinical development programmes as vice president and head of clinical development at Morphosys in Germany.
Previously she held a variety of senior positions in clinical development and medical affairs. She served as a global clinical programme head in oncology development, and more recently as EU head of medical affairs in haematology at Novartis.
Prior to Novartis, she spent five years with Novo Nordisk as head of global medical affairs, biopharmaceuticals in Denmark and later, director of clinical development in haematology in the US.
